contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


curasight-announces-broadening-and-extension-of-patent-protection-for-utracer

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Curasight är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom utveckling av teknologiska produkter. Produktportföljen har sitt huvudsakliga fokus inom utvecklingen av innovativa teknologier för diagnostik och behandling av cancer baserat på målstyrd PET-avbildning och radionuklidterapi. Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.

Curasight

 Issuance of new patent related to uTRACE® will broaden protection Patent coverage has been extended by 751 days and now expires 2035 Strengthened patent protection significantly enhances the...

<div class="abstract"><ul>	<li>Issuance of new patent related to uTRACE® will broaden protection</li>	<li>Patent coverage has been extended by 751 days and now expires 2035</li>	<li>Strengthened patent protection significantly enhances the potential financial value of uTRACE® </li></ul>Copenhagen, Denmark, 01 October 2025 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today the issuance of US patent 12,409,240 B2 which expands the protection of the company's uPAR diagnostic platform, uTRACE. The patent term has also been extended by 751 days (more than 2 years) so that it now expires in 2035. &nbsp;This significantly extends the patent protection for uTRACE, enhancing the platform's potential value across current and future cancer programs. </div>"We are committed to ensuring robust patent protection for our technology as we advance our theranostic approach, combining our diagnostic platform uTRACE® and our therapeutic platform uTREAT® to improve cancer diagnosis and treatment. This new US patent for uTRACE not only reinforces the protection of our proprietary technology and extends the platform's patent life, but also adds important value to our ongoing prostate cancer program with Curium - as well as to any potential future development of uTRACE in additional cancer cancer indications", said Curasight CEO Ulrich Krasilnikoff. About Curasight's theranostic platformCurasight's radiopharmaceutical theranostic platform builds on uPAR-targeting peptides labelled either with radioisotopes suitable for imaging, uTRACE®, or labelled with radioisotopes suitable for radioligand therapy, uTREAT®. The target, uPAR, is expressed in the majority of solid tumors and is a marker of cancer aggressiveness.<div></div>

Curasight announces broadening and extension of patent protection for uTRACE®

USA:s Black Week ledde till överraskande inköp

Uppgångsvecka bakom oss, Tyskland gick vidare med sin megabudget

Finlands ekonomiska tillväxt: ”Varje dag och varje natt tänker jag på dig”

Nedgångsvecka bakom oss, AI-oron når även obligationsmarknaden

USA:s sysselsättningssiffror: En ljusglimt i Feds fyr